treatment
-
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically for…
Read More » -
Caregiver Support & Resources
Understanding and Addressing Pelvic Floor Dysfunction: A Comprehensive Guide to Symptoms, Risks, and Treatment
The often-jokingly dismissed inability to control bladder function during a cough, laugh, or sneeze is, in fact, a significant indicator…
Read More » -
Alzheimer’s & Dementia Care
FDA Reviews Expanded Approval for Subcutaneous Leqembi Iqlik, Offering At-Home Treatment from Initiation
The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) submitted by Biogen and…
Read More » -
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval to Auvelity (dextromethorphan-bupropion), marking a significant advancement in the management…
Read More » -
Alzheimer’s & Dementia Care
Study reports Alzheimer’s treatment gains in long-term care
Top-line data emanating from the BEACON study, a real-world observational investigation, indicate that Zunveyl (benzgalantamine) was linked to significant provider-reported…
Read More » -
Disability Support & Independent Living
FDA Withdraws Approval of Wellcovorin, GSK’s Branded Leucovorin, Amidst Complex History of Autism Treatment Claims
United States regulators have formally withdrawn the Food and Drug Administration’s (FDA) approval for Wellcovorin, the branded version of leucovorin…
Read More » -
Alzheimer’s & Dementia Care
Health Canada Conditionally Approves Leqembi, Marking a Pivotal Shift in Alzheimer’s Treatment by Targeting Underlying Disease Cause
Health Canada has granted conditional approval for Leqembi (lecanemab), a groundbreaking therapy co-developed by Eisai and Biogen, for specific adults…
Read More » -
Palliative & Hospice Care
Alzheimer’s Disease, Amyloid, and Antibodies: Experts Grapple with Evolving Definitions and Treatment Dilemmas
The landscape of Alzheimer’s disease diagnosis and treatment is undergoing a profound transformation, driven by advancements in understanding the disease’s…
Read More » -
Alzheimer’s & Dementia Care
FDA Reviews Expanded Approval for Leqembi Iqlik: Subcutaneous Option for Early Alzheimer’s Treatment Initiation
The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) seeking expanded approval for…
Read More » -
Palliative & Hospice Care
Palliative Care: A Beacon of Hope Amidst the Spectrum of Cancer Treatment
The landscape of cancer treatment often presents patients and their families with a stark dichotomy: the fervent hope for a…
Read More »
